Overactive Bladder Drug Market

Overactive Bladder Drug Market contains market size and forecasts of Overactive Bladder Drug in global, including the following market information:

Global Overactive Bladder Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Overactive Bladder Drug Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Overactive Bladder Drug companies in 2021 (%)

The global Overactive Bladder Drug market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Anticholinergics Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Overactive Bladder Drug include Astellas Pharma, Inc. (Japan), Pfizer, Inc. (US), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (US), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan) and Sanofi (France), etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Overactive Bladder Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Overactive Bladder Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Overactive Bladder Drug Market Segment Percentages, by Type, 2021 (%)

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Others

Global Overactive Bladder Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Overactive Bladder Drug Market Segment Percentages, by Application, 2021 (%)

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

Global Overactive Bladder Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Overactive Bladder Drug Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Overactive Bladder Drug revenues in global market, 2017-2022 (Estimated), ($ millions)

Key companies Overactive Bladder Drug revenues share in global market, 2021 (%)

Key companies Overactive Bladder Drug sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Overactive Bladder Drug sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Astellas Pharma, Inc. (Japan)

Pfizer, Inc. (US)

Teva Pharmaceutical Industries Limited (Israel)

Allergan, Plc (Ireland)

Medtronic plc (Ireland)

Mylan N.V. (US)

Endo International plc (Ireland)

Hisamitsu Pharmaceutical Co., Inc. (Japan)

Sanofi (France)

Apotex, Inc. (Canada)

Cogentix Medical, Inc. (US)

Aurobindo Pharma Limited (India)